The US FDA has approved dexmedetomidine sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. This marks the first FDA-approved treatment specifically indicated for self-administration at home during episodes of acute agitation associated with these conditions. Read more: nei.global/21293
In this episode, Dr. Andy Cutler and Dr. Lois Choi-Kain review common myths about personality disorders beyond borderline personality disorder (BPD) and what clinicians may miss when they focus on BPD alone. They discuss dimensional approaches to diagnosis, clinical clues that personality pathology may be present alongside other psychiatric conditions, and how challenges in clinical trials shape the evidence base for treatment. Listen now: nei.global/e294
Earlier this month the FDA granted 510(k) clearance to a prescription digital therapeutic targeting these negative symptoms of schizophrenia in adults with clinically stable positive symptoms. It is intended to complement clinician-managed outpatient care, including antipsychotic therapy. Read more: nei.global/21234
47
The countdown is on. One week until the 2026 NEI Fall Congress!
Get ready to see the science come to life. Watch neurotransmitters in motion, visualize how medications modulate brain circuits, and follow clinical cases as they unfold. With sessions shaped around the clinical decisions you face every day, you’ll build a deeper understanding of psychopharmacology and leave with practical strategies you can use Monday morning.
Whether you’re joining us in Colorado Springs or online, we look forward to seeing you November 5–8!
There’s still time to join us! Sign up now nei.global/26fall-reg
#NEICongress #Psychiatry
A recent clinical practice review examines current evidence and recommendations for the assessment, diagnosis, and management of ADHD in adults. Read more nei.global/21232
hashtag#ADHDAwarenessMonth
64
Two weeks until psychiatry’s brightest minds come together! Join us November 5–8 at the 2026 NEI Fall Congress for the latest treatment updates, engaging sessions, and clinical pearls you can use Monday morning.
Connect with us in Colorado or virtually from anywhere. There’s still time to register: nei.global/26fall-2weeks
When repetitive behaviors look similar, what helps guide treatment?
On today’s NEI Podcast, Dr. Andy Cutler and Dr. Jon Grant explore OCD, trichotillomania, and skin-picking disorder. Learn how distinguishing compulsions from body-focused repetitive behaviors can guide treatment, from behavioral therapies to medication and emerging approaches.
Listen now nei.global/e293
2
89
Your front-row seat to psychiatry education is wherever you are. Join the 2026 NEI Fall Congress live via simulcast, November 5–8, for four days of online CME/CE for mental health professionals. Explore advances in psychopharmacology with leading experts and gain practical strategies for the clinical challenges you encounter every day.
Bring fresh perspectives to your practice, all from the comfort of your home or office.
Explore the agenda and register nei.global/26fall-simulcast
1
57
NEI Saturday Morning Live is starting soon! Log in now to hear from two leading experts exploring the role of long-acting injectables in optimizing outcomes for patients with serious mental illness. Hara Oyedeji, DNP, PMHNP-BC, MSEd, and Leslie Citrome, MD, MPH, will share practical, evidence-based strategies for determining when and why to consider an LAI, selecting an appropriate formulation, and initiating and maintaining treatment. Join the conversation live and have your questions answered during the Q&A. Log in here ➡ nei.global/smloct17
51
Learn what’s new, what works, and how to use it! With so many long-acting injectable (LAI) formulations available, including the newly FDA-approved once-monthly subcutaneous olanzapine extended-release injectable suspension, how do you choose the right option for your patient?
Join us Saturday, October 17, for a free, half-day virtual CE program exploring when and why to consider an LAI, how to select an appropriate formulation, and practical strategies for initiating and maintaining treatment.
Register Here 👉 nei.global/26sml-register
56
There’s still time to register! Join us Saturday, October 17, for a free, half-day virtual CE program exploring how long-acting injectable (LAI) formulations can help optimize outcomes for patients with serious mental illness.
Gain practical strategies for determining when and why to consider an LAI, selecting an appropriate formulation, and successfully initiating and maintaining treatment.
Register today and earn FREE CME/CE credits: nei.global/26sml-register
1
59
Could orexin signaling open a new direction in attention-deficit/hyperactivity disorder (ADHD) treatment? Orexin-2 receptor agonism is emerging as a potential research direction in ADHD. Explore the biological rationale and preliminary findings for ALKS 7290, an investigational oral treatment. Read more nei.global/21230
68
Join us this Saturday, October 17, for a free online CME/CE program exploring the role of long-acting injectables (LAIs) in optimizing treatment outcomes for patients with serious mental illness.
Hear expert insights from Hara Oyedeji, DNP, PMHNP-BC, MSEd, and Leslie Citrome, MD, MPH, and earn 2.5 CME/CE credits from the comfort of home.
Register for free 👉 nei.global/26sml-oct-17
3
149
The U.S. Food and Drug Administration has approved the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia. The new formulation requires no loading dose, oral supplementation, or post-injection monitoring. Read more: nei.global/21227
Psychedelic therapeutics are making headlines. What does the evidence mean for clinical practice? At the upcoming 2026 NEI Fall Congress, Dr. Roger McIntyre will examine the promise and limitations of psilocybin, MDMA-assisted therapy, and other emerging approaches. Explore how trial design, treatment durability, safety, and regulatory decisions shape the path from research to responsible care.
Explore the science behind the headlines this November at NEI Fall Congress. Join us in person or online via simulcast. nei.global/26fall-c13
4
2
126
This episode of The PsychopharmaStahlogy Show features Drs. Andrew Cutler and Stephen Stahl in conversation with Dr. Tiffany Greenwood on the genetic and trait-based links between bipolar disorder and creativity. They explore how temperament, personality, and cognitive style may occupy the space between madness and genius, the role of dopamine, evolutionary explanations for why bipolar risk persists, and why stabilizing mood doesn't have to mean losing creativity. Listen now: nei.global/e292
49
The U.S. Food and Drug Administration (FDA) has approved tavapadon for the treatment of Parkinson disease in adults. Tavapadon is an oral, once-daily selective partial agonist at dopamine D1 and D5 receptors. It was studied without levodopa in early disease and as an adjunct to levodopa in patients with motor fluctuations. Read more nei.global/21226
1
73
Only one month until your psychopharmacology journey begins! Join us at the 2026 NEI Fall Congress to deepen your knowledge, discover practical clinical strategies, and connect with fellow mental health professionals.
Attend in Colorado Springs or online via simulcast, November 5–8. Register today: nei.global/26cngf-reg
3
187
October is ADHD Awareness Month. ADHD affects patients across the lifespan, yet changes in symptom presentation and the presence of co-occurring conditions can make accurate identification and treatment more complex.
Health care professionals play an essential role in advancing ADHD awareness through evidence-based evidence-based education and individualized care, health care professionals can improve recognition, reduce stigma, and support better outcomes. See more: nei.global/21224
#ADHDAwarenessMonth #MentalHealth
1
58
Join us for a free, half-day virtual CE program exploring the how, why, when, and for whom of utilizing long-acting injectable (LAI) formulations to treat serious mental illness (SMI), including early in the disease course. Register today: nei.global/26sml-oct-17
1
83



